A solid tumor diagnostics lead at a multinational pharmaceutical company discusses their opinions around MRD and monitoring across different cancer indications, with their optimism for these technologies focused on CRC. This stakeholder works at a company that conducts ctDNA testing across thousands of patients in clinical trials every year, and is familiar with the MRD offerings from vendors such as Foundation Medicine, Natera, Guardant, Personalis, NeoGenomics, Invitae, Inivita, and Grail. This stakeholder dives deeply into the pain points around sequencing tumors, outlines future trends around using WGS and methylation sequencing, and expresses a sentiment that the MRD/monitoring market will eventually be dominated by 1-2 key players.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care